Health Catalyst (NASDAQ:HCAT) Earns Neutral Rating from Cantor Fitzgerald

Health Catalyst (NASDAQ:HCAT)‘s stock had its “neutral” rating reissued by research analysts at Cantor Fitzgerald in a report released on Monday,Benzinga reports.

Other research analysts have also issued research reports about the company. Canaccord Genuity Group cut their price objective on Health Catalyst from $5.00 to $2.00 and set a “buy” rating for the company in a report on Friday, March 13th. Citigroup dropped their target price on shares of Health Catalyst from $2.75 to $1.75 and set a “neutral” rating for the company in a research report on Friday, March 13th. Stephens cut their price target on shares of Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating for the company in a research note on Friday, March 13th. Stifel Nicolaus decreased their price target on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a report on Friday, March 13th. Finally, Raymond James Financial set a $3.00 price objective on shares of Health Catalyst in a report on Friday, March 13th. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Hold” and a consensus target price of $2.80.

Health Catalyst Trading Down 2.1%

Shares of HCAT stock opened at $1.49 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.89 and a current ratio of 1.89. Health Catalyst has a 52-week low of $0.96 and a 52-week high of $4.74. The company has a market capitalization of $109.50 million, a PE ratio of -0.59 and a beta of 1.63. The business’s fifty day moving average is $1.37 and its 200 day moving average is $2.08.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Thursday, March 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). The business had revenue of $74.68 million for the quarter, compared to analysts’ expectations of $73.99 million. Health Catalyst had a negative return on equity of 4.30% and a negative net margin of 57.20%. On average, equities research analysts anticipate that Health Catalyst will post -0.28 EPS for the current fiscal year.

Institutional Trading of Health Catalyst

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC bought a new position in shares of Health Catalyst in the fourth quarter worth approximately $25,000. Pilgrim Partners Asia Pte Ltd bought a new stake in Health Catalyst during the 3rd quarter valued at $39,000. Cresset Asset Management LLC bought a new stake in Health Catalyst during the 2nd quarter valued at $39,000. FNY Investment Advisers LLC purchased a new stake in Health Catalyst during the 3rd quarter valued at $45,000. Finally, Focus Partners Wealth bought a new stake in Health Catalyst in the 1st quarter worth $46,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.